CD19-CAR-T2 Cells

BIOLOGICAL2 trials

Sponsors

Guangdong Provincial People's Hospital, Nanfang Hospital, Southern Medical University

Conditions

Acute LeukemiaB Cell LeukemiaB Cell Lymphoma

Phase 1

Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia

Guangdong Provincial People's HospitalAcute Leukemia

Start: 2016-01-31End: 2019-09-30Target: 30Updated: 2017-09-11

Phase 2

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

CompletedNCT04605666

Nanfang Hospital, Southern Medical UniversityB Cell Leukemia, B Cell Lymphoma

Start: 2020-05-01End: 2023-12-31Updated: 2024-08-20

Related Papers

Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study

Blood2025-11-03

Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial

Journal of Translational Medicine2025-05-276 citations

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Blood2023-11-021 citations

Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)

BMJ Open2020-02-0149 citations

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.

2018-02-2085 citations